Shopping Cart
- Remove All
Your shopping cart is currently empty
Olinvacimab
🥰Excellent
Catalog No. T77108Cas No. 2095504-49-5
Alias TTAC-0001, TTAC0001
Olinvacimab (TTAC-0001) is a human monoclonal antibody targeting VEGFR-2/KDR with anti-angiogenic activity that blocks tumor angiogenesis and may be used to study solid tumors.
Olinvacimab
Olinvacimab
🥰Excellent
Purity: 95%
Catalog No. T77108Alias TTAC-0001, TTAC0001Cas No. 2095504-49-5
Olinvacimab (TTAC-0001) is a human monoclonal antibody targeting VEGFR-2/KDR with anti-angiogenic activity that blocks tumor angiogenesis and may be used to study solid tumors.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $169 | In Stock | |
| 5 mg | $448 | In Stock | |
| 10 mg | $715 | In Stock | |
| 25 mg | $1,080 | In Stock | |
| 50 mg | $1,460 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "Olinvacimab"
Sorafenib
Cited
Bay 43-9006
T0093L284461-73-0
Sorafenib (Bay 43-9006) is a multikinase inhibitor that targets Raf-1, B-Raf, VEGFR2, VEGFR3, VEGFR4, PDGFRβ, FLT3, c-Kit, and others (IC50=6/22/90/15/20/20/57/58 nM) with oral activity. It exhibits antitumor properties and can induce autophagy, apoptosis, and agonistic iron death.
- $34
Size
QTY
CitedPazopanib
GW786034
T0097L444731-52-6
Pazopanib (GW786034) is an inhibitor of protein tyrosine kinases that inhibits VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms (IC50=10/30/47/84/74/140/146 nM). Pazopanib has antitumor activity.
- $42
Size
QTY
Regorafenib Cited
Fluoro-Sorafenib, BAY 73-4506
T1792755037-03-7
Regorafenib (BAY 73-4506) is an orally active, multi-targeted receptor tyrosine kinase inhibitor that inhibits RET, C-RAF, VEGFR2, c-Kit, VEGFR1, and PDGFRβ, exhibiting both antitumor and anti-angiogenic activity.
- $30
Size
QTY
CitedAxitinib
Cited
AG-013736
T1452319460-85-0
Axitinib (AG-013736) is a multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1, VEGFR2, VEGFR3, and PDGFRβ (IC50=4/20/0.4/2 nM). Axitinib has antitumor activity and is used in the treatment of renal cell carcinoma.
- $33
Size
QTY
CitedNintedanib Cited
Intedanib, BIBF 1120
T1777656247-17-5
Nintedanib (Intedanib) is a triple vascular kinase inhibitor that inhibits VEGFR1, VEGFR2, and VEGFR3 (IC50=34/13/13 nM), FGFR1, FGFR2, and FGFR3 (IC50=69/37/108 nM), PDGFRα, and PDGFRβ (IC50=59/65 nM). Nintedanib has antitumor activity and inhibits tumor growth by inhibiting angiogenesis.
- $38
Size
QTY
CitedRibociclib Cited
LEE011
T61991211441-98-3
Ribociclib (LEE011) is an orally available, and highly specific CDK4/6 inhibitor (IC50：10/39 nM).
- $36
Size
QTY
CitedRegorafenib monohydrate
T1792L1019206-88-2
Regorafenib Monohydrate is a novel oral multikinase inhibitor with IC50 values of 13, 4.2, 46, 22, 7, 1.5, 2.5, 28, 19 nM for VEGFR1, murine VEGFR2, murine VEGFR3, PDGFR-β, KIT, RET, RAF-1, B-RAF and B-RAF(V600E) respectively.
- $30
Size
QTY
Sorafenib tosylate Cited
Bay 43-9006
T0093475207-59-1
Sorafenib tosylate (Bay 43-9006) is a potent multikinase inhibitor (IC50s: 6/20/22 nM for Raf-1/VEGFR-3/B-Raf).
- $37
Size
QTY
CitedLenvatinib mesylate Cited
E7080 (mesylate)
T8541857890-39-2
Lenvatinib mesylate (E7080 (mesylate)) is an oral and multi-targeted inhibitor of VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, with potent antitumor activities.
- $34
Size
QTY
CitedTaxifolin Cited
Dihydroquercetin, (+)-Taxifolin, (+)-Dihydroquercetin
T1738480-18-2
Taxifolin (Dihydroquercetin) is a flavonoid in many plants such as Taxus chinensis, Siberian larch, Cedrus deodara and so on.
- $30
Size
QTY
CitedSanguinarine chloride Cited
Sanguinarium chloride, Pseudochelerythrine chloride
T01295578-73-4
Sanguinarine chloride (Pseudochelerythrine chloride), a benzophenanthridine alkaloid, stimulates apoptosis by activating the production of reactive oxygen species (ROS).
- $50
Size
QTY
CitedSelect Batch
Concentration:5.67 mg/mL
Purity:95%
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Chemical Properties
| Description | Olinvacimab (TTAC-0001) is a human monoclonal antibody targeting VEGFR-2/KDR with anti-angiogenic activity that blocks tumor angiogenesis and may be used to study solid tumors. |
| Targets&IC50 | VEGF:0.23 nM (Kd), VEGF D to VEGFR2:7.0 nM, VEGF C to VEGFR2:6.3 nM |
| In vitro | Olinvacimab binds VEGF and blocks its binding to the receptor KDR with a Kd value of 0.23 nM.[1] Olinvacimab inhibits the binding of VEGF-165, VEGF-C, and VEGF-D to VEGFR-2 with IC50 values of 8.7 nM, 6.3 nM, and 7.0 nM, respectively.[1] Olinvacimab (0.5-30 μg/mL; 30 min) reduced the phosphorylation levels of VEGFR-2/KDR and ERK.[1] Olinvacimab was shown to reduce VEGFR-2/KDR and ERK phosphorylation levels. [1] Olinvacimab (1, 15, 20 mg/mL; 30 min) blocks VEGF-stimulated proliferation of human umbilical vein endothelial cells. [1] Olinvacimab (20 mg/mL; 30 min) Reduces VEGF-induced migration of human umbilical vein endothelial cells. [1] Olinvacimab (5, 10, 20 μg; 20 hours) demonstrated dose-dependent inhibition of angiogenesis and disruption of tubular structure. [1] |
| In vivo | Olinvacimab (100 ng; subcutaneous injection, single dose) Inhibits angiogenesis in vivo. [1] |
| Alias | TTAC-0001, TTAC0001 |
| Cas No. | 2095504-49-5 |
Storage & Solubility Information
| Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy Olinvacimab | purchase Olinvacimab | Olinvacimab cost | order Olinvacimab | Olinvacimab in vivo | Olinvacimab in vitro
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.